A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)



Status:Completed
Conditions:Shingles, Infectious Disease
Therapuetic Areas:Dermatology / Plastic Surgery, Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:10/21/2012
Start Date:February 2012
End Date:April 2013
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease


This is a randomized, double-blind, placebo-controlled study to assess the safety and
tolerability of V212 when administered to adults with autoimmune disease.


This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the
safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including
patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel
disease, systemic lupus erythematosus, multiple sclerosis, and other similar diseases.

Inclusion Criteria:

- Diagnosed with an autoimmune disease

- Clinically stable disease for at least 30 days before enrollment

- Not likely to undergo hematopoietic stem cell transplantation during the study period

- Receiving at least one parenteral or oral biologic agent, such as a TNF alpha
inhibitor, or a parenteral or oral non-biologic therapy, at a stable dose for at
least 3 months, with no planned or anticipated changes

- History of varicella, antibodies to VZV, or residence for at least 30 years in a
country with endemic VZV infection, or if participant is less than 30 years old,
attended primary or secondary school in a country with endemic VZV infection

Exclusion Criteria:

- Prior history of Herpes Zoster (shingles) within 1 year before enrollment

- Prior varicella or zoster vaccine

- Active central nervous system lupus erythematosus requiring therapeutic intervention
within 90 days of enrollment

- Prior or planned therapy containing rituximab or other anti-CD20 monoclonal
antibodies from 3 months before enrollment through 28 days postdose 4

- Systemic corticosteroid therapy, prednisone, or equivalent over 40 mg daily at the
time of enrollment
We found this trial at
18
sites
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
?
mi
from
Galveston, TX
Click here to add this to my saved trials
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville Beach, Florida 32250
?
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Melville, NY
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Thousand Oaks, California 91360
?
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
?
mi
from
Worcester, MA
Click here to add this to my saved trials